SCHEMBL935331

SCHEMBL935331

C=C(C)C(=O)NCCCn1ccnc1

nearest known ligand 0.60

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.59
SMN1; SMN2 Q16637 3/20 0.59
QPCT Q16769 5/20 0.57
ALDH1A1 P00352 2/20 0.57
NPC1 O15118 1/20 0.57
CYP1A2 P05177 1/20 0.56
CYP3A4 P08684 1/20 0.56
CYP2D6 P10635 1/20 0.56
CYP2C9 P11712 1/20 0.56
HSD17B10 Q99714 1/20 0.56
LMNA P02545 2/20 0.56
POLB P06746 1/20 0.56
GAA P10253 1/20 0.55
CA12 O43570 1/20 0.55
CA1 P00915 1/20 0.55
CA2 P00918 1/20 0.55
CA9 Q16790 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6686022 0.99 L3MBTL1 (0.58) L3MBTL1SMN1; SMN2QPCTALDH1A1NPC1
SCHEMBL16798907 0.91 ALDH1A1 (0.49) L3MBTL1SMN1; SMN2QPCTALDH1A1NPC1
SCHEMBL19198443 0.90 IDE (0.51) L3MBTL1SMN1; SMN2QPCTALDH1A1NPC1
SCHEMBL21669765 0.88 TBXAS1 (0.52) L3MBTL1SMN1; SMN2ALDH1A1LMNAPOLB
SCHEMBL13655177 0.88 SMN1; SMN2 (0.72) L3MBTL1SMN1; SMN2QPCTALDH1A1NPC1
SCHEMBL21669751 0.87 TBXAS1 (0.54) L3MBTL1SMN1; SMN2ALDH1A1LMNAPOLB
SCHEMBL21669744 0.87 TBXAS1 (0.54) L3MBTL1SMN1; SMN2ALDH1A1LMNAPOLB
SCHEMBL21669747 0.87 TBXAS1 (0.54) L3MBTL1SMN1; SMN2ALDH1A1LMNAPOLB
SCHEMBL21669749 0.87 TBXAS1 (0.54) L3MBTL1SMN1; SMN2ALDH1A1LMNAPOLB
SCHEMBL21669740 0.87 TBXAS1 (0.54) L3MBTL1SMN1; SMN2ALDH1A1LMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 248 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7582684-B2 Macroporous ion exchange resins 3M INNOVATIVE PROPERTIES COMPANY (US) 2009-09-01 US claimed
EP-0707077-B1 Methods for capture and selective release of nucleic acids using weakly basic polymer and amplification of same ORTHO CLINICAL DIAGNOSTICS INC (US) 2004-11-17 EP claimed
EP-0702006-B1 Weakly basic polymerizable monomers and polymers prepared therefrom JOHNSON & JOHNSON CLIN DIAG (US) 2000-05-10 EP claimed
US-5582988-A PRECIPITAION OF NUCLEIC ACID AND CATION POLYMER AT ACIDIC PH; ADJUSTMENT OF PH TO RELEASE NUCLEIC ACID JOHNSON & JOHNSON CLINICAL DIAGNOSTICS, INC. (US) 1996-12-10 US claimed
US-5523368-A Weakly basic polymerizable monomers and polymers prepared therefrom JOHNSON & JOHNSON CLINICAL DIAGNOSTICS, INC. (US) 1996-06-04 US claimed
EP-0707077-A2 Methods for capture and selective release of nucleic acids using weakly basic polymer and amplification of same JOHNSON & JOHNSON CLINICAL DIAGNOSTICS, INC. (US) 1996-04-17 EP claimed
EP-0702006-A1 Weakly basic polymerizable monomers and polymers prepared therefrom JOHNSON & JOHNSON CLINICAL DIAGNOSTICS, INC. (US) 1996-03-20 EP claimed
JP-8173194-A None JP disclosed
US-12630582-B2 Method for biomaterial purification and kits thereof Life Technologies Corporation (US) 2026-05-19 US disclosed
US-20250367610-A1 Block Copolymers Grafted to Porous Polymeric Substrate SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) 2025-12-04 US disclosed
CN-114144248-B Imidazolium zwitterionic polymerizable compounds and ophthalmic devices incorporating same 强生视力健公司 2025-06-03 CN disclosed
EP-4543575-A1 BLOCK COPOLYMERS GRAFTED TO POROUS POLYMERIC SUBSTRATE Solventum Intellectual Properties Company (US) 2025-04-30 EP disclosed
EP-2588219-B1 FILTER PLATE ARTICLE HAVING A WATER-ABSORBENT FILTER ASSEMBLY NEOGEN FOOD SAFETY US HOLDCO CORP (US) 2024-05-29 EP disclosed
EP-0702006-B1 Weakly basic polymerizable monomers and polymers prepared therefrom JOHNSON & JOHNSON CLIN DIAG (US) 2000-05-10 EP disclosed
US-5582988-A PRECIPITAION OF NUCLEIC ACID AND CATION POLYMER AT ACIDIC PH; ADJUSTMENT OF PH TO RELEASE NUCLEIC ACID JOHNSON & JOHNSON CLINICAL DIAGNOSTICS, INC. (US) 1996-12-10 US disclosed
JP-H08173194-A CAPTURE AND SELECTIVE RELEASE OF NUCLEIC ACID USING WEAKLY BASIC POLYMER AND AMPLIFYING OF THE SAME JOHNSON & JOHNSON CLINICAL DIAGNOSTICS INC 1996-07-09 JP disclosed
US-5523368-A Weakly basic polymerizable monomers and polymers prepared therefrom JOHNSON & JOHNSON CLINICAL DIAGNOSTICS, INC. (US) 1996-06-04 US disclosed
EP-0707077-A2 Methods for capture and selective release of nucleic acids using weakly basic polymer and amplification of same JOHNSON & JOHNSON CLINICAL DIAGNOSTICS, INC. (US) 1996-04-17 EP disclosed
EP-0702006-A1 Weakly basic polymerizable monomers and polymers prepared therefrom JOHNSON & JOHNSON CLINICAL DIAGNOSTICS, INC. (US) 1996-03-20 EP disclosed
US-5434270-A Weakly basic polymerizable monomers and polymers prepared therefrom EASTMAN KODAK COMPANY (US) 1995-07-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12630582-B2 Method for biomaterial purification and kits thereof CD68, FIBP, BMP2 L3MBTL1 1406/4885SMN1; SMN2 3006/4885QPCT 1286/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.